PFIZER INC (PFE) Quick Ratio
- Quick ratio · latest quarter: Value 0.64×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28..
Quick ratio
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 0.64× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-28. $20.75B ÷ $32.65B ≈ 0.64× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 20.75B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 32.65B USD | Liabilities, Current |
| Cash and equivalents | 976.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 7.28B USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 12.49B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 9.95B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-28 | $20.75B | $32.65B | $976.00M | $7.28B | $12.49B | $9.95B | 0.64× |
| 2026-03-29 | $22.48B | $34.35B | $1.70B | $8.19B | $12.59B | $10.67B | 0.65× |
| 2025-12-31 | $22.20B | $36.98B | $1.14B | $9.18B | $11.87B | $10.65B | 0.60× |
| 2025-09-28 | $25.73B | $36.60B | $1.34B | $10.12B | $14.26B | $11.47B | 0.70× |
| 2025-06-29 | $23.24B | $37.73B | $1.64B | $9.53B | $12.08B | $11.67B | 0.62× |
| 2025-03-30 | $27.23B | $36.45B | $1.43B | $13.95B | $11.85B | $10.85B | 0.75× |
| 2024-12-31 | $23.39B | $42.99B | $1.04B | $10.88B | $11.46B | $10.85B | 0.54× |
| 2024-09-29 | $22.39B | $43.21B | $1.09B | $6.85B | $14.45B | $11.72B | 0.52× |
| 2024-06-30 | $16.85B | $43.82B | $1.05B | $4.40B | $11.39B | $11.45B | 0.38× |
| 2024-03-31 | $19.93B | $40.50B | $719.00M | $8.22B | $10.99B | $10.89B | 0.49× |
| 2023-12-31 | $18.43B | $47.79B | $2.85B | $4.40B | $11.18B | $10.19B | 0.39× |
| 2023-10-01 | $40.48B | $31.14B | $3.15B | $26.25B | $11.09B | $10.20B | 1.30× |
| 2023-07-02 | $36.95B | $34.65B | $2.63B | $24.09B | $10.23B | $10.31B | 1.07× |
| 2023-04-02 | $30.59B | $36.56B | $2.17B | $16.12B | $12.30B | $9.54B | 0.84× |
| 2022-12-31 | $30.11B | $42.14B | $416.00M | $18.74B | $10.95B | $8.98B | 0.71× |
| 2022-10-02 | $37.55B | $44.31B | $1.30B | $20.18B | $16.08B | $9.51B | 0.85× |
| 2022-07-03 | $42.56B | $47.41B | $1.78B | $25.62B | $15.15B | $10.45B | 0.90× |
| 2022-04-03 | $33.03B | $39.27B | $2.47B | $17.34B | $13.22B | $9.98B | 0.84× |
| 2021-12-31 | $35.44B | $42.67B | $1.94B | $22.01B | $11.48B | $9.06B | 0.83× |
| 2021-10-03 | $36.75B | $41.80B | $1.97B | $22.89B | $11.90B | $8.64B | 0.88× |
| 2021-07-04 | $26.98B | $35.66B | $2.37B | $14.03B | $10.59B | $8.95B | 0.76× |
| 2021-04-04 | $19.92B | $26.65B | $1.77B | $8.29B | $9.86B | $8.49B | 0.75× |
| 2020-12-31 | $19.42B | $25.92B | $1.78B | $9.71B | $7.93B | $8.05B | 0.75× |
| 2020-09-27 | $19.46B | $34.15B | $1.59B | $7.86B | $10.01B | $9.29B | 0.57× |
| 2020-06-28 | $18.60B | $32.72B | $1.80B | $7.67B | $9.13B | $8.56B | 0.57× |
| 2020-03-29 | $14.84B | $33.89B | $2.15B | $2.81B | $9.88B | $8.42B | 0.44× |
| 2019-12-31 | $16.72B | $37.30B | $1.30B | $6.69B | $8.72B | $8.28B | 0.45× |
| 2019-09-29 | $16.49B | $36.97B | $2.79B | $4.27B | $9.44B | $8.22B | 0.45× |
| 2019-06-30 | $16.60B | $32.03B | $1.78B | $5.03B | $9.79B | $8.23B | 0.52× |
| 2019-03-31 | $18.72B | $29.42B | $1.94B | $7.18B | $9.60B | $8.03B | 0.64× |
| 2018-12-31 | $24.25B | $31.86B | $1.14B | $15.09B | $8.03B | $7.51B | 0.76× |
| 2018-09-30 | $24.84B | $29.01B | $3.56B | $11.26B | $10.02B | $8.18B | 0.86× |
| 2018-07-01 | $20.80B | $32.16B | $2.70B | $8.22B | $9.87B | $8.07B | 0.65× |
| 2018-04-01 | $18.76B | $27.36B | $2.30B | $7.01B | $9.45B | $8.15B | 0.69× |
| 2018-01-01 | (m) | (m) | (m) | (m) | $8.23B | $7.57B | (m) |
| 2017-12-31 | $27.06B | $30.43B | $1.34B | $17.49B | $8.22B | $7.58B | 0.89× |
| 2017-10-01 | (m) | $28.22B | $2.78B | (m) | $10.00B | $7.92B | (m) |
| 2017-07-02 | (m) | $27.18B | $2.58B | (m) | $9.48B | $7.58B | (m) |
| 2017-04-02 | (m) | $24.86B | $4.06B | (m) | $8.89B | $7.42B | (m) |
| 2016-12-31 | (m) | $31.11B | $2.60B | (m) | $8.22B | $6.78B | (m) |
| 2016-10-02 | (m) | $34.76B | $2.09B | (m) | $9.84B | $7.51B | (m) |
| 2016-07-03 | (m) | $32.10B | $3.41B | (m) | $9.14B | $7.61B | (m) |
| 2016-04-03 | (m) | $28.73B | $2.56B | (m) | $9.03B | $7.58B | (m) |
| 2015-12-31 | (m) | $29.40B | $3.64B | (m) | $8.18B | $7.51B | (m) |
| 2015-09-27 | (m) | $27.84B | $3.10B | (m) | $9.54B | $7.68B | (m) |
| 2015-06-28 | (m) | $24.14B | $3.67B | (m) | $8.95B | $5.80B | (m) |
| 2015-03-29 | (m) | $20.22B | $3.56B | (m) | $8.92B | $5.79B | (m) |
| 2014-12-31 | (m) | $21.63B | $3.34B | (m) | $8.67B | $5.66B | (m) |
| 2014-09-28 | (m) | $19.92B | $2.44B | (m) | $9.96B | $6.36B | (m) |
| 2014-06-29 | (m) | $21.94B | $3.41B | (m) | $10.39B | $6.25B | (m) |
| 2014-03-30 | (m) | $24.79B | $2.86B | (m) | $9.40B | $6.07B | (m) |
| 2013-12-31 | (m) | $23.37B | $2.18B | (m) | $9.36B | $6.17B | (m) |
| 2013-09-29 | (m) | $20.37B | $2.05B | (m) | $11.37B | $6.48B | (m) |
| 2013-06-30 | (m) | $23.45B | $2.44B | (m) | $11.52B | $6.28B | (m) |
| 2013-03-31 | (m) | $27.54B | $2.13B | (m) | $12.73B | $7.04B | (m) |
| 2012-12-31 | (m) | $28.62B | $10.39B | (m) | $12.38B | $7.06B | (m) |
| 2012-09-30 | (m) | $29.13B | $4.51B | (m) | $12.52B | $7.52B | (m) |
| 2012-07-01 | (m) | $30.80B | $3.03B | (m) | $12.88B | $7.00B | (m) |
| 2012-04-01 | (m) | $27.09B | $2.93B | (m) | $14.18B | $7.19B | (m) |
| 2011-12-31 | (m) | $28.07B | $3.54B | (m) | $13.61B | $7.77B | (m) |
| 2011-10-02 | (m) | $27.86B | $3.71B | (m) | $15.75B | $8.43B | (m) |
| 2011-07-03 | (m) | $30.47B | $3.10B | (m) | $15.19B | $8.60B | (m) |
| 2011-04-03 | (m) | $29.17B | $730.00M | (m) | $15.18B | $8.47B | (m) |
| 2010-12-31 | (m) | $28.61B | $1.74B | (m) | $14.61B | $8.40B | (m) |
| 2010-10-03 | (m) | $24.17B | $2.18B | (m) | $14.30B | $8.77B | (m) |
| 2010-07-04 | (m) | $24.68B | $1.88B | (m) | $14.01B | $9.51B | (m) |
| 2010-04-04 | (m) | $25.92B | $1.76B | (m) | $13.61B | $10.13B | (m) |
| 2010-01-04 | (m) | (m) | $1.98B | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $37.23B | $1.98B | (m) | $14.64B | $12.40B | (m) |
| 2009-09-27 | (m) | $23.99B | $4.23B | (m) | $10.55B | $5.06B | (m) |
| 2009-06-28 | (m) | $26.11B | $2.24B | (m) | $10.45B | $4.99B | (m) |
| 2009-03-29 | (m) | (m) | $1.25B | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $27.01B | $2.12B | (m) | $8.96B | $4.38B | (m) |
| 2008-09-28 | (m) | (m) | $1.26B | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | $820.00M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $3.41B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $1.83B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |